N-[5-({3-[5-(Acetyl-hydroxy-amino)-pentylcarbamoyl]-propionyl}-hydroxy-amino)-pentyl]-N'-{5-[(3-bromo-adamantane-1-carbonyl)-amino]-pentyl}-N'-hydroxy-succinamide

ID: ALA4203650

Chembl Id: CHEMBL4203650

PubChem CID: 145977783

Max Phase: Preclinical

Molecular Formula: C36H61BrN6O9

Molecular Weight: 801.82

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)C12CC3CC(CC(Br)(C3)C1)C2

Standard InChI:  InChI=1S/C36H61BrN6O9/c1-27(44)41(50)18-8-2-5-15-38-30(45)11-13-32(47)42(51)19-9-3-6-16-39-31(46)12-14-33(48)43(52)20-10-4-7-17-40-34(49)35-22-28-21-29(23-35)25-36(37,24-28)26-35/h28-29,50-52H,2-26H2,1H3,(H,38,45)(H,39,46)(H,40,49)

Standard InChI Key:  XZAZRPUYELYOME-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4203650

    ---

Associated Targets(Human)

SK-N-BE(2)-M17 (195 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Astrocyte (46 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 801.82Molecular Weight (Monoisotopic): 800.3683AlogP: 3.81#Rotatable Bonds: 25
Polar Surface Area: 208.92Molecular Species: NEUTRALHBA: 9HBD: 6
#RO5 Violations: 2HBA (Lipinski): 15HBD (Lipinski): 6#RO5 Violations (Lipinski): 3
CX Acidic pKa: 7.92CX Basic pKa: 0.48CX LogP: 0.63CX LogD: 0.50
Aromatic Rings: Heavy Atoms: 52QED Weighted: 0.03Np Likeness Score: -0.18

References

1. Telfer TJ, Liddell JR, Duncan C, White AR, Codd R..  (2017)  Adamantyl- and other polycyclic cage-based conjugates of desferrioxamine B (DFOB) for treating iron-mediated toxicity in cell models of Parkinson's disease.,  27  (8): [PMID:28285915] [10.1016/j.bmcl.2017.03.001]

Source